http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/glioblastomamultiforme/Significant_vaccine-enhanced_immune_response_in_malignant_brain_tumour_103173.shtml Glioblastoma Multiforme Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a patient's immune response and clinical outcome, according to an article in the July 15 issue of the journal Cancer Research. Tue, 15 Jul 2008 01:21:44 PST http://www.rxpgnews.com/glioblastomamultiforme/Significant_vaccine-enhanced_immune_response_in_malignant_brain_tumour_103173.shtml http://www.rxpgnews.com/glioblastomamultiforme/Simultaneous_implantation_of_radioactive_seeds_and_chemotherapy_wafers_promising_in_glioblastoma_multiforme_treatment_84555.shtml Glioblastoma Multiforme In the battle against malignant brain tumors, dual implantation of radioactive seeds and chemotherapy wafers following surgery showed promising results in a study led by specialists at the Neuroscience Institute at the University of Cincinnati (UC) and University Hospital. Sun, 20 Jan 2008 09:31:57 PST http://www.rxpgnews.com/glioblastomamultiforme/Simultaneous_implantation_of_radioactive_seeds_and_chemotherapy_wafers_promising_in_glioblastoma_multiforme_treatment_84555.shtml http://www.rxpgnews.com/glioblastomamultiforme/New_vaccine_to_fight_glioblastoma_multiforme_devel_4214_4214.shtml Glioblastoma Multiforme A vaccine to fight an aggressive form of brain tumour has been developed by US scientists, who say it can delay progression of the cancer. Tue, 02 May 2006 22:40:00 PST http://www.rxpgnews.com/glioblastomamultiforme/New_vaccine_to_fight_glioblastoma_multiforme_devel_4214_4214.shtml http://www.rxpgnews.com/glioblastomamultiforme/Discovery_could_change_the_way_doctors_treat_gliob_2828_2828.shtml Glioblastoma Multiforme Researchers at UCLA's Jonsson Cancer have identified key characteristics in certain deadly brain tumors that make them 51 times more likely to respond to a specific class of drugs than tumors in which the molecular signature is absent. The discovery of the telltale molecular signature — the expression of a mutant protein and the presence of a tumor suppressor protein called PTEN — will allow researchers to identify patients who are likely to respond to the drug treatment before they undergo therapies that are not likely to work, said Dr. Paul Mischel, a UCLA associate professor of pathology and laboratory medicine and a Jonsson Cancer Center researcher. Fri, 11 Nov 2005 00:46:00 PST http://www.rxpgnews.com/glioblastomamultiforme/Discovery_could_change_the_way_doctors_treat_gliob_2828_2828.shtml http://www.rxpgnews.com/glioblastomamultiforme/Glioblastoma_Gene_Variations_Can_Predict_Treatment_2826_2826.shtml Glioblastoma Multiforme Screening glioblastoma brain tumors for two gene variations can reliably predict which tumors will respond to a specific class of drugs, a new study shows. The findings may lead to improved treatment for this devastating disease. The study was funded in part by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), and appears in the November 10, 2005, issue of the New England Journal of Medicine. Glioblastomas are the most common malignant brain tumors in adults, and they are notoriously difficult to treat successfully. "The survival with glioblastoma is usually a year on average, and that hasn't improved in a while, so this is a very serious and challenging disease," says Paul Mischel, M.D., of the David Geffen School of Medicine and Jonsson Comprehensive Cancer Center at the University of California , Los Angeles (UCLA), who led the study. While drugs are available to help treat glioblastoma, they often have minimal effect, and doctors usually have time to try only one or two treatments before the disease causes severe impairment. Glioblastomas feature many genetic variations that affect their response to different treatments. Researchers are trying to identify these genetic factors and to tease apart how they affect the disease in order to determine which patients are the most likely to benefit from specific drugs. Fri, 11 Nov 2005 00:20:00 PST http://www.rxpgnews.com/glioblastomamultiforme/Glioblastoma_Gene_Variations_Can_Predict_Treatment_2826_2826.shtml http://www.rxpgnews.com/glioblastomamultiforme/P-gp_system_let_JV-1-36_pass_into_the_brain_to_tre_2126_2126.shtml Glioblastoma Multiforme A compound that kills cancer can sneak past the blood brain barrier, which protects the brain from foreign substances, to do its work in fighting a particularly invasive brain cancer, according to a new Saint Louis University animal study published in the Proceedings of the National Academy of Sciences Online Early Edition the week of Aug. 22. Tue, 23 Aug 2005 19:56:00 PST http://www.rxpgnews.com/glioblastomamultiforme/P-gp_system_let_JV-1-36_pass_into_the_brain_to_tre_2126_2126.shtml http://www.rxpgnews.com/glioblastomamultiforme/Combined_gene_therapy_can_eliminate_glioblastoma_m_2059_2059.shtml Glioblastoma Multiforme Despite aggressive treatment, glioblastoma multiforme (GBM) – the most common and deadly of brain cancers – usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain. In laboratory studies, this type of gene therapy has proved almost completely effective. But in clinical trials, it has had limited effectiveness. Mon, 15 Aug 2005 17:44:00 PST http://www.rxpgnews.com/glioblastomamultiforme/Combined_gene_therapy_can_eliminate_glioblastoma_m_2059_2059.shtml